Medindia LOGIN REGISTER
Medindia

IPS Cell Technology Used for Modeling of Congenital Amegakaryocytic Thrombocytopenia

by Kathy Jones on Aug 5 2013 7:26 PM

Researchers reveal that they have managed to induce iPS cells generated from a patient with congenital amegakaryocytic thrombocytopenia to differentiate into blood cells.

 IPS Cell Technology Used for Modeling of Congenital Amegakaryocytic Thrombocytopenia
Researchers led by Shinji Hirata and Professor Koji Eto at CiRA reveal that they have managed to induce iPS cells generated from a patient with congenital amegakaryocytic thrombocytopenia (CAMT) to differentiate into blood cells in vitro which were then used to conduct a detailed study of the differences between these cells and cells from healthy subjects.
The researchers found that, in humans, thrombopoietin receptors are essential not only to the maintenance of the multipotent hematopoietic progenitor population and the production of platelets, but also to erythropoiesis (red blood cell production).

CAMT is caused by the congenital loss of thrombopoietin receptor-mediated intracellular signaling, resulting in a state of severe thrombocytopenia from birth and leading in the infant period to bone marrow failure and gradual depletion first of red blood cells and then of white blood cells. This grave illness requires bone marrow transplant for the patient to survive, but the lack of an adequate experimental model has hitherto been a hindrance to elucidating its pathology. In the present study, with the cooperation of one CAMT patient who has now received a bone marrow transplant and recovered, iPS cells (CAMT iPS cells) were generated and induced in vitro to differentiate into blood cells, whose behavior was analyzed in detail.

In the CAMT iPS cells, as in the CAMT patient's original blood cells, the thrombopoietin receptors were not functional. To check their ability to differentiate into megakaryocytes, platelets, erythrocytes (red blood cells), and other cell types, these iPS cells were differentiated into multipotent hematopoietic progenitors, which can in turn differentiate into a range of different blood cell types. It was found that the multipotent hematopoietic progenitors derived from the CAMT iPS cells, unlike the iPS cells from healthy subjects, had impaired ability to develop not only into megakaryocytes and platelets, but also into erythrocytes. They did however retain some ability to differentiate into white blood cells. These characteristics closely reflect the pathological state seen in CAMT patients.



Source-Eurekalert


Advertisement